News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
579,652 Results
Type
Article (19036)
Company Profile (166)
Press Release (560377)
Multimedia
Podcasts (78)
Webinars (13)
Section
Business (198377)
Career Advice (702)
Deals (30735)
Drug Delivery (86)
Drug Development (65632)
Employer Resources (54)
FDA (12399)
Job Trends (11095)
News (287842)
Policy (24144)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (814)
Accelerated approval (39)
ADA (26)
Adcomms (10)
Allergies (140)
Alliances (41808)
ALS (140)
Alzheimer's disease (1260)
Antibody-drug conjugate (ADC) (338)
Approvals (12997)
Artificial intelligence (495)
ASCO (219)
Autoimmune disease (241)
Automation (40)
Bankruptcy (319)
Best Places to Work (8366)
BIO (47)
BIOSECURE Act (10)
Biosimilars (184)
Biotechnology (103)
Bladder cancer (149)
Brain cancer (55)
Breast cancer (596)
Cancer (4396)
Cardiovascular disease (344)
Career advice (606)
Career pathing (14)
CAR-T (215)
CDC (8)
Celiac Disease (1)
Cell therapy (604)
Cervical cancer (41)
Clinical research (58735)
Collaboration (1676)
Commercialization (2)
Company closure (1)
Compensation (1417)
Complete response letters (60)
COVID-19 (1278)
CRISPR (81)
C-suite (1011)
Cystic fibrosis (123)
Data (6491)
Decentralized trials (1)
Denatured (23)
Depression (124)
Dermatology (66)
Diabetes (436)
Diagnostics (4791)
Digital health (43)
Diversity (3)
Diversity, equity & inclusion (16)
Drug discovery (255)
Drug pricing (126)
Drug shortages (15)
Duchenne muscular dystrophy (223)
Earnings (80697)
Editorial (25)
Employer branding (5)
Employer resources (50)
Events (99061)
Executive appointments (938)
FDA (15458)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (19)
Frontotemporal dementia (27)
Funding (1193)
Gene editing (161)
Generative AI (35)
Gene therapy (452)
GLP-1 (667)
Government (2004)
Grass and pollen (5)
Guidances (331)
Healthcare (11026)
Hematology (128)
HIV (55)
Huntington's disease (28)
IgA nephropathy (94)
Immunology and inflammation (166)
Immuno-oncology (74)
Indications (190)
Infectious disease (1508)
Inflammatory bowel disease (172)
Inflation Reduction Act (9)
Influenza (96)
Intellectual property (288)
Interviews (93)
IPO (13967)
IRA (33)
Job creations (3104)
Job search strategy (549)
JPM (29)
Kidney cancer (20)
Labor market (39)
Layoffs (251)
Leadership (11)
Legal (6580)
Liver cancer (54)
Longevity (21)
Lung cancer (616)
Lymphoma (335)
Machine learning (35)
Management (18)
Manufacturing (878)
Marketing (10)
MASH (162)
Medical affairs (1)
Medical device (9247)
Medtech (9378)
Mergers & acquisitions (17905)
Metabolic disorders (1049)
mRNA (104)
Multiple sclerosis (139)
NASH (15)
Neurodegenerative disease (291)
Neuropsychiatric disorders (68)
Neuroscience (2388)
Neurotech (1)
NextGen: Class of 2026 (3893)
Non-profit (1254)
Now hiring (23)
Obesity (422)
Opinion (158)
Ovarian cancer (173)
Pain (241)
Pancreatic cancer (220)
Parkinson's disease (271)
Partnered (20)
Patents (563)
Patient recruitment (568)
Peanut (39)
People (50560)
Pharmaceutical (45)
Pharmacy benefit managers (23)
Phase 1 (18118)
Phase 2 (25830)
Phase 3 (19153)
Pipeline (8023)
Policy (163)
Postmarket research (2126)
Preclinical (7522)
Press Release (49)
Prostate cancer (233)
Psychedelics (30)
Radiopharmaceuticals (266)
Rare diseases (831)
Real estate (4460)
Recruiting (20)
Regulatory (19602)
Reports (22)
Research institute (953)
Resumes & cover letters (94)
Rett syndrome (40)
RNA editing (12)
RSV (52)
Schizophrenia (144)
Series A (216)
Series B (153)
Service/supplier (4)
Sickle cell disease (97)
Special edition (11)
Spinal muscular atrophy (112)
Sponsored (15)
Startups (2783)
State (2)
Stomach cancer (8)
Supply chain (94)
Tariffs (71)
The Weekly (53)
Vaccines (502)
Venture capital (53)
Weight loss (223)
Women's health (96)
Worklife (4)
Date
Last 7 days (326)
Last 30 days (1337)
Last 365 days (23056)
2026 (13184)
2025 (23306)
2024 (27246)
2023 (31379)
2022 (40749)
2021 (43341)
2020 (39861)
2019 (29680)
2018 (22644)
2017 (24683)
2016 (23526)
2015 (29425)
2014 (25669)
2013 (22076)
2012 (24098)
2011 (24440)
2010 (23674)
Location
Africa (465)
Alabama (79)
Alaska (2)
Arizona (319)
Arkansas (13)
Asia (30102)
Australia (4134)
California (12210)
Canada (3347)
China (1001)
Colorado (491)
Connecticut (445)
Delaware (267)
Europe (54502)
Florida (1854)
Georgia (391)
Hawaii (2)
Idaho (49)
Illinois (833)
India (87)
Indiana (543)
Iowa (14)
Japan (541)
Kansas (115)
Kentucky (36)
Louisiana (28)
Maine (27)
Maryland (1315)
Massachusetts (8409)
Michigan (316)
Minnesota (581)
Mississippi (5)
Missouri (101)
Montana (27)
Nebraska (16)
Nevada (114)
New Hampshire (68)
New Jersey (3085)
New Mexico (18)
New York (3014)
North Carolina (1465)
North Dakota (4)
Northern California (6082)
Ohio (292)
Oklahoma (16)
Oregon (27)
Pennsylvania (2338)
Puerto Rico (26)
Rhode Island (36)
South America (732)
South Carolina (78)
South Dakota (1)
Southern California (5025)
Tennessee (139)
Texas (1948)
United States (41405)
Utah (370)
Vermont (1)
Virginia (256)
Washington D.C. (51)
Washington State (952)
West Virginia (2)
Wisconsin (100)
Wyoming (1)
579,652 Results for "biostar pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Breaking the “Untreatable": Biostar Pharma’s UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
December 16, 2025
·
3 min read
Press Releases
The FDA Granted Orphan Drug Designation to Biostar Pharma’s Utidelone for the Treatment of Pancreatic Cancer
September 26, 2025
·
4 min read
Press Releases
Novotech and Biostar Establish Strategic Partnership Following Biostar’s HKEX Listing
November 13, 2024
·
2 min read
Press Releases
Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio
June 28, 2026
·
5 min read
Biostar Pharma Successively Achieved First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule (UTD2)
September 16, 2025
·
5 min read
Biotech Bay
100% CBR! FDA Granted ODD to Biostar Pharma’s Utidelone Capsule (UTD2) for the Treatment of Gastric Cancer
Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their key pipeline product UTD2 (utidelone capsule) had been granted an Orphan Drug Designation (ODD) by the FDA for the treatment of gastric cancer.
March 21, 2024
·
4 min read
Press Releases
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada
July 15, 2026
·
2 min read
Biotech Bay
73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis
Biostar Pharma, Inc. announced today that their core pipeline product utidelone injectable (UTD1) had been granted an Orphan Drug Designation (ODD) by the FDA for the treatment of breast cancer brain metastasis (BCBM).
March 29, 2024
·
3 min read
Artificial intelligence
Alnylam hops on AI train with up to $2B Inceptive partnership
Alnylam Pharmaceuticals will leverage Inceptive Nucleics’ generative machine learning models to accelerate the development of RNA interference therapies.
June 4, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
May 5, 2026
·
6 min read
1 of 57,966
Next
